<DOC>
	<DOC>NCT00160615</DOC>
	<brief_summary>The safety and efficacy of L059 will be evaluated in patients who completed "N165 Clinical Trial of L059". They will receive L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs</brief_summary>
	<brief_title>Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>1. Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059 2. Patients/the parent or guardian wish to continue treatment with L059 and to enter N165 Followup Study, and also the investigator admit the necessity of the repeated intake of the investigational drug for the patients. 1. Patients who had not participate in N165 Clinical Trial of L059. 2. Patients who had participated in N165 Clinical Trial of L059 with no intention of entering the followup study taking the same medication. 3. Patients had not been in compliance with requirements of Protocol for N165 Clinical Trial of L059 in the course of the study.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Epilepsy, Partial,</keyword>
	<keyword>Keppra, levetiracetam</keyword>
</DOC>